drug
(azelastine hydrochloride + fluticasone propionate)
Marketedupdated 3mo agoby Mylan Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (azelastine hydrochloride + fluticasone propionate)
- phase3Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
- phase1Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray
- —Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- phase2A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 24, 2026
27 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Aug 24, 2026patentUS 8168620*PED27d
- Feb 24, 2026formulationUS 8168620
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that